DRUG (Bright Minds Biosciences) OCF Yield %: -2.26 (As of Jun. 27, 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $65.79
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences OCF Yield %?

Bright Minds Biosciences DRUG +3.35% 34 OCF Yield % is -2.26 as of Jun. 27, 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, Bright Minds Biosciences ranks better than 69.56% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Bright Minds Biosciences's Trailing 12-Month Cash Flow from Operations is $-14.44 Mil, and Market Cap is $617.47 Mil. Therefore, Bright Minds Biosciences's OCF Yield % for today is -2.26%.

The historical rank and industry rank for Bright Minds Biosciences's OCF Yield % or its related term are showing as below:

DRUG' s OCF Yield % Range Over the Past 10 Years
Min: -2.26   Med: 0   Max: -2.26
Current: -2.26

During the past 6 years, the highest OCF Yield % of Bright Minds Biosciences was -2.26%. The lowest was -2.26%. And the median was %.

DRUG's OCF Yield % is ranked better than
69.56% of 1419 companies
in the Biotechnology industry
Industry Median: -8.48 vs DRUG: -2.26

Bright Minds Biosciences's OCF Margin % for the quarter that ended in Mar. 2026 was %.

Bright Minds Biosciences OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Bright Minds Biosciences OCF Yield % Related Terms

Bright Minds Biosciences OCF Yield % Historical Data

* Premium members only.

The historical data trend for Bright Minds Biosciences's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Minds Biosciences OCF Yield % Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
OCF Yield %
Get a 7-Day Free Trial -6.83 -47.08 -86.01 -25.81 -1.36

Bright Minds Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.64 -5.54 -0.79 -2.78 -3.76

DRUG vs VRTX, REGN, ALNY: OCF Yield % Comparison

For the Biotechnology subindustry, Bright Minds Biosciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's OCF Yield % falls into.


DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bright Minds Biosciences OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Bright Minds Biosciences's OCF Yield % for the fiscal year that ended in Sep. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-6.283 / 463.19976
=-1.36%

Bright Minds Biosciences's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-6.739 * 4 / 715.98164
=-3.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -2.26 mean?
Bright Minds Biosciences (DRUG) has a OCF Yield % of -2.26 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bright Minds Biosciences and its competitors. According to the industry distribution chart, Bright Minds Biosciences ranks #432 out of 1419 companies in the Biotechnology industry, placing it in the top 30.4%.
Is Bright Minds Biosciences' OCF Yield % too high?
Bright Minds Biosciences' current OCF Yield % is -2.26. Based on the distribution chart, Bright Minds Biosciences ranks #432 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bright Minds Biosciences ranks #432 out of 1419 companies for OCF Yield %. This puts Bright Minds Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current OCF Yield % is -2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current OCF Yield % of -2.26. The current OCF Yield % is -2.26. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current OCF Yield % is -2.26 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.79
Price